pre-IPO PHARMA

COMPANY OVERVIEW

Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Neurodegenerative Disease
  • Oncology

  • WEBSITE

    https://www.kymeratx.com/#


    CAREER WEBSITE

    https://www.kymeratx.com/#


    SOCIAL MEDIA


    INVESTORS

    6-dimensions-capital aju-ib-investment amgen-ventures atlas-venture bessemer-venture-partners hatteras-venture-partners lilly-ventures merck pfizer-ventures sanofi-ventures


    PRESS RELEASES


    Jul 9, 2020

    Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients


    Jun 11, 2020

    Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology


    Jun 3, 2020

    Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis


    Mar 12, 2020

    Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform


    Feb 5, 2020

    Kymera Therapeutics to Present Preclinical Data on its First-in-Class Selective and Potent Oral IRAK4 Degraders in Cutaneous Inflammation


    For More Press Releases


    Google Analytics Alternative